FGF7 and hematologic disorder: The only agent approved by the Food and Drug Association (USA) is palifermin (recombinant human keratinocyte growth factor), but its use is limited to patients with hematologic malignancies who received myelotoxic therapy, besides being limited due to the considerable associated cost (16).